© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Tenaya Therapeutics, Inc. (TNYA) stock declined over -1.74%, trading at $0.68 on NASDAQ, down from the previous close of $0.70. The stock opened at $0.69, fluctuating between $0.68 and $0.71 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 04, 2026 | 0.69 | 0.71 | 0.68 | 0.68 | 1.19M |
| Sep 03, 2026 | 0.70 | 0.71 | 0.69 | 0.70 | 1.55M |
| Sep 02, 2026 | 0.70 | 0.71 | 0.69 | 0.70 | 1.21M |
| Sep 01, 2026 | 0.69 | 0.70 | 0.68 | 0.69 | 1.07M |
| Aug 31, 2026 | 0.69 | 0.70 | 0.67 | 0.69 | 1.5M |
| Aug 28, 2026 | 0.70 | 0.70 | 0.69 | 0.69 | 1.11M |
| Aug 27, 2026 | 0.70 | 0.71 | 0.69 | 0.70 | 1.24M |
| Aug 26, 2026 | 0.69 | 0.72 | 0.69 | 0.70 | 934.89K |
| Aug 25, 2026 | 0.67 | 0.71 | 0.67 | 0.70 | 1.73M |
| Aug 24, 2026 | 0.70 | 0.70 | 0.66 | 0.67 | 4.02M |
| Aug 21, 2026 | 0.69 | 0.72 | 0.69 | 0.70 | 1.12M |
| Aug 20, 2026 | 0.71 | 0.73 | 0.69 | 0.69 | 1.52M |
| Aug 19, 2026 | 0.72 | 0.73 | 0.70 | 0.71 | 1.94M |
| Aug 18, 2026 | 0.70 | 0.71 | 0.68 | 0.70 | 2.21M |
| Aug 17, 2026 | 0.72 | 0.73 | 0.68 | 0.70 | 4.28M |
| Aug 14, 2026 | 0.74 | 0.75 | 0.73 | 0.73 | 1.53M |
| Aug 13, 2026 | 0.76 | 0.79 | 0.73 | 0.73 | 1.72M |
| Aug 12, 2026 | 0.77 | 0.79 | 0.75 | 0.76 | 2.13M |
| Aug 11, 2026 | 0.75 | 0.77 | 0.74 | 0.75 | 2M |
| Aug 10, 2026 | 0.73 | 0.75 | 0.72 | 0.74 | 2.39M |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Employees | 70 |
| Beta | 2.79 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |